Source comparison
MOTS-c Insulin Sensitivity Results Timeline Comparison
48–72 hours AMPK phosphorylation detectable in muscle tissue No change in fasting glucose or HbA1c Mechanism activated but not yet systemic Too early for clinical assessment. Continue dosing 2–4 weeks GLUT4 translocation sustained, mitochondrial glucose oxidat
This comparison does not assign a generated winner or score.
- 48–72 hours
- AMPK phosphorylation detectable in muscle tissue
- No change in fasting glucose or HbA1c
- Mechanism activated but not yet systemic
- Too early for clinical assessment. Continue dosing
- 2–4 weeks
- GLUT4 translocation sustained, mitochondrial glucose oxidation increases 15–25%
- Possible reduction in post-meal glucose spikes (1-hour postprandial)
- Subjective energy improvement, reduced post-meal fatigue
- Cellular response established. Biomarker lag expected
- 6–8 weeks
- Mitochondrial biogenesis begins, PGC-1α upregulation
- Fasting glucose drops 8–15 mg/dL, oral glucose tolerance improves
- First measurable clinical improvement in standard lab tests
- Expected timeline for mild-to-moderate insulin resistance
- 10–12 weeks
- Sustained AMPK activity, hepatic glucose output reduction
- HbA1c reduction of 0.3–0.6%, fasting insulin may drop 20–30%
- Comprehensive metabolic improvement across glucose and lipid markers
- Full effect timeline for severe baseline resistance
- Post-cessation (5–7 days)
- AMPK activity returns to baseline, GLUT4 translocation reverses
- Fasting glucose rises back toward baseline within 10–14 days
- Metabolic gains not permanent without continued dosing
- MOTS-c is a metabolic modulator, not a cure